T cell response to new melanoma antigen linked to relapse-free survival

Oct 20, 2008

Melanoma patients infused with a special type of tumor-fighting T cell are more likely to survive without relapse, suggests a new study by researchers in France. Their report will be published online on October 20 in the Journal of Experimental Medicine.

One treatment option for patients with late-stage melanoma involves removing natural cancer-fighting T cells from the tumor, expanding their numbers in culture dishes, and then re-infusing them into the patient. This strategy—called adoptive immunotherapy— causes tumor regression in about half the patients treated, some of whom survive for decades without relapse.

The French team, lead by Dr. Nathalie Labarriere, studied the infused cells from 30 stage III melanoma patients who had received adoptive immunotherapy between 1994 and 1998. Among the cells taken from a patient who has remained tumor-free for more than a decade, they found naturally-arising T cells that recognized a new protein, which they dubbed "meloe-1." Meloe-1, the group found, is highly expressed in melanoma cells but not in normal skin cells or in other types of cancer.

When they looked at the transferred cells from the other patients, they found meloe-1-specific T cells in 5 of the 9 patients who remained relapse-free, but in none of the 21 patients who relapsed. The association of meloe-1-specific T cells with relapse-free survival suggests that amplifying these T cells in culture may be one way to improve the efficacy of adoptive immunotherapy. The team has also succeeded in finding meloe-1 T cells in patients' circulating blood—a much more accessible source than tumor tissue.

Source: Rockefeller University

Explore further: Scientists identify which genes are active in muscles of men and women

add to favorites email to friend print save as pdf

Related Stories

Venom gets good buzz as potential cancer-fighter

Aug 11, 2014

Bee, snake or scorpion venom could form the basis of a new generation of cancer-fighting drugs, scientists will report here today. They have devised a method for targeting venom proteins specifically to malignant cells while ...

Adult stem cells found to suppress cancer while dormant

Dec 20, 2013

Researchers at UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have discovered a mechanism by which certain adult stem cells suppress their ability to initiate skin cancer during their dormant ...

Recommended for you

Scientists discover gene controlling muscle fate

11 hours ago

Scientists at the University of New Mexico have moved a step closer to improving medical science through research involving muscle manipulation of fruit flies. They discovered in the flight muscles of Drosophila ...

Study clues to aging bone loss

11 hours ago

In Canada, bone fractures due to osteoporosis affect one in three women and one in five men over their lifetimes, costing the health care system more than $2.3 billion a year.

User comments : 0